The
dementia is a group of specific disorders where different parts of the brain
degenerate causing symptoms such as memory loss, difficulty with aspects of
functioning such as speech or behavior and eventually difficulty with all life
functions. Alzheimer’s is the most common form of dementia
accounting for approximately 70% of this population. While the
ability to prevent and treat many other chronic diseases is improving, this has
not been the case with Alzheimer’s and other dementias. Some of the
facts include:
· Alzheimer’s
is the only disease in the list of the 10 most common disease associated deaths
that there is no available treatment that may prevent, cure or slow its
progression.
· Approximately
200,000 adults in U.S. under the age of 65 years are already diagnosed with the
disease.
· Most
will die from the disease within 4 to 8 years.
· It
is perhaps the most costly disease involving greatest direct medical costs
combined with great costs for long-term care.
· One
in five (20%) individuals > 65 years have MCI
(pre-Alzheimer’s) and many will convert to Alzheimer’s within 5 years.
· Currently
there are approximately 5 million adults with Alzheimer’s.
· This
will double within 15 years and triple within 35 years resulting in a
staggering $21 trillion in direct costs over that interval.
Given
the inability of treatment to modify the disease once it is well established,
the focus of favorably impacting the epidemic is shifting to prevention and
aggressive early treatment. Up to this point there had been little
progress as treatment has been almost entirely focused on drug
interventions. To date there have been 244 drug trials for Alzheimer’s,
and 243 produced no positive results in altering the course of the
disease. Only two classes of drugs have been approved for treatment, but
they only “soften” symptoms in the short term and do not alter the progression
of the disease.
The
reasons for the disappointing treatment results are thought to relate to the
fact that Alzheimer’s origins are multifactorial. Dale Bredesen, MD, the
Director of Neurodegenerative Disease Research, David Geffen School of Medicine at
UCLA, describes the disease process as being like water leaking
through a barn roof that has 36 holes. Drug therapies have targeted one
hole which does little to stop the roof from leaking during a heavy rain.
The 36
factors that Dr. Bredesen discusses include genetic predispositions, environmental factors,
metabolic factors and lifestyle driven factors. While some are
non-modifiable such as genetics and population aging, the majority are
modifiable and therefore can be targeted with treatment. The
lifestyle/metabolic related factors are diverse such as vitamin B12 deficiency,
low cell omega-3 levels, pre-diabetes, chronic high insulin levels, high
inflammation and many more.
Dr.
Bredesen has developed the first treatment approach that has actually
demonstrated effectiveness in preventing the conversion of MCI into full
Alzheimer’s as well as reversing mild Alzheimer’s itself. The process
involves measuring extensive numbers of variables and finding the collection
that are imbalanced and contributing to the disease process in that given
person. Once the “triggers” are identified a diverse treatment program
specific to each individual’s imbalances is designed and implemented.
One of
the most interesting findings in the first group of patients treated with this
process was that those who had genetic predispositions such as the apoE4
variant had equally good outcomes with intensive lifestyle management.
This is a very important finding as 75 million Americans have the abnormal
apoE4 genetic predisposition and without changes to how things are currently
being done, 30 million are destined to develop Alzheimer’s disease. While
individuals with the genetic risk have a greater tendency to develop the
disease, they appear to respond well to tight metabolic regulation. The
genetic factors simply appear to make them more susceptible to errors in
metabolic/lifestyle factors.
The
population is aging, and age is a major risk factor for Alzheimer’s.
Approximately one in six individuals have genetic variations that increase
their risk. However, a rapidly changing factor that appears to be driving
a significant portion of the increase in Alzheimer’s are the increases in
metabolic/lifestyle factors. Genetics and age are non-modifiable.
Fortunately, a major part of this puzzle is highly modifiable, and strong
changes in this area have shown great promise in preventing and helping this
disease.
No comments:
Post a Comment